empagliflozin glp-1 New Guidelines for Type 2 Diabetes in 2025 GLP-1 Receptor Agonists | New

Current clinical evidence remains limited, making provider consultation essential before starting or continuing these medications while breastfeeding

A new KFF analysis estimates that 3.8 million Medicare Part D enrollees could qualify for the Medicare GLP-1 Bridge program, which began July 1 and provides temporary coverage of GLP-1s for weight reduction for eligible beneficiaries through December 2027.

Curcumin activated GPR55 and induced serum-response element- and serum-response factor-mediated transcription, which were inhibited by Rho kinase and GPR55 antagonists

GLP-1 Weight Loss Drugs linked to rare EYE STROKE that can cause sudden blindness

Philippines Glucagon Like Peptide-1 (GLP-1) Receptor Agonist Market is valued at around $34.6 Mn in 2022 and is projected to reach $65.2 Mn by 2030, exhibiting a CAGR of 8.23% during the forecast period 2023-2030.